A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC
Phase 3, Open-Label Study to Characerize the Incidence and Severity of Diarrhea in Patients with Early stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis
A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy
Phase III open label, randomized, Study of the cancer stem cell inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in metastatic pancreatic adenocarcinoma
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUSCAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
A Phase 2 Study of the Efficacy and Safety Of ACP-196 in Subjects with Relapsed/ Refractory CLL and Intolerant of Ibrutinib Therapy
Phase 3, open-label trial of lenalidomide and low-dose dexamethasone with or without pembrolizumab (MK-3475) in newly diagnosed, treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation
An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease
Non-Randomized Open-Label Phase 11 Study to Assess Oliparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade or High-Grade Endometriod Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that Have Received at Least 1 Ptior Line of Chemotherapy